Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Spotlight On UK Penny Stocks With At Least £40M Market Cap

In This Article:

The United Kingdom's financial markets have recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China and global economic uncertainties. Despite these broader market pressures, certain investment opportunities can still be found in smaller or newer companies known as penny stocks. Although the term "penny stock" might seem outdated, these investments can offer substantial value when backed by strong financial health, presenting potential growth opportunities for investors willing to explore this niche sector.

Top 10 Penny Stocks In The United Kingdom

Name

Share Price

Market Cap

Financial Health Rating

Ultimate Products (LSE:ULTP)

£0.63

£53.19M

★★★★★☆

LSL Property Services (LSE:LSL)

£2.76

£284.98M

★★★★★☆

Helios Underwriting (AIM:HUW)

£2.20

£159.37M

★★★★★☆

Warpaint London (AIM:W7L)

£3.80

£290.83M

★★★★★★

Foresight Group Holdings (LSE:FSG)

£3.695

£417.56M

★★★★★★

Polar Capital Holdings (AIM:POLR)

£3.725

£359.08M

★★★★★★

Cairn Homes (LSE:CRN)

£1.596

£989.91M

★★★★★☆

Begbies Traynor Group (AIM:BEG)

£0.972

£155.02M

★★★★★★

QinetiQ Group (LSE:QQ.)

£3.838

£2.11B

★★★★★☆

Van Elle Holdings (AIM:VANL)

£0.345

£37.33M

★★★★★★

Click here to see the full list of 386 stocks from our UK Penny Stocks screener.

Let's dive into some prime choices out of the screener.

ECO Animal Health Group

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ECO Animal Health Group plc, with a market cap of £40.66 million, develops, registers, and markets pharmaceutical products for animals globally.

Operations: The company's revenue is primarily derived from its Pharmaceuticals segment, which generated £84.60 million.

Market Cap: £40.66M

ECO Animal Health Group plc, with a market cap of £40.66 million, is actively pursuing growth through strategic mergers and acquisitions in the preventative segment of animal health. The recent submission of its ECOVAXXIN® vaccine to the European Medicines Agency indicates progress in its vaccines portfolio. Financially, ECO has no debt and maintains strong asset coverage for both short and long-term liabilities, though its Return on Equity is low at 1.6%. Despite past earnings declines, the company has recently turned profitable with earnings forecasted to grow significantly at 30.65% per year, trading below estimated fair value by 53%.

AIM:EAH Financial Position Analysis as at Apr 2025
AIM:EAH Financial Position Analysis as at Apr 2025

Litigation Capital Management

Simply Wall St Financial Health Rating: ★★★★☆☆